Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-16 09:16 am Unchanged | 2025-04-16 | 13D | Elevation Oncology, Inc. ELEV | BML Investment Partners, L.P. | 5,890,934 9.900% | 0 (Unchanged) | Filing History |
| 2025-03-26 7:11 pm Purchase | 2025-03-21 | 13G | Elevation Oncology, Inc. ELEV | BML Investment Partners, L.P. | 5,890,934 9.900% | 5,890,934 (New Position) | Filing History |
| 2025-02-14 1:34 pm Sale | 2024-12-31 | 13G | Elevation Oncology, Inc. ELEV | Logos Global Management LP | 0 0.000% | -3,500,000 (Position Closed) | Filing History |
| 2025-02-06 2:52 pm Sale | 2024-12-31 | 13G | Elevation Oncology, Inc. ELEV | GOLDMAN SACHS GROUP INC GS | 1,683,356 2.800% | -2,833,221 (-62.73%) | Filing History |
| 2025-02-05 4:28 pm Unchanged | 2024-12-31 | 13G | Elevation Oncology, Inc. ELEV | Farallon Capital Partners, L.P. | 3,527,482 6.000% | 0 (Unchanged) | Filing History |
| 2025-02-04 3:45 pm Purchase | 2024-12-31 | 13G | Elevation Oncology, Inc. ELEV | BlackRock Inc. BLK | 3,163,180 5.400% | 3,163,180 (New Position) | Filing History |
| 2025-01-30 9:33 pm Sale | 2024-12-31 | 13G | Elevation Oncology, Inc. ELEV | The Vanguard Group | 2,610,045 4.410% | -461,535 (-15.03%) | Filing History |
| 2024-11-14 7:50 pm Sale | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | Point72 Asset Management, L.P. | 500,000 0.800% | -3,540,000 (-87.62%) | Filing History |
| 2024-11-14 7:05 pm Sale | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | Logos Global Management LP | 3,500,000 5.900% | -150,000 (-4.11%) | Filing History |
| 2024-11-14 6:45 pm Sale | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | ORBIMED ADVISORS LLC | 2,441,275 4.000% | -558,725 (-18.62%) | Filing History |
| 2024-11-14 4:46 pm Sale | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | Great Point Partners, LLC | 0 0.000% | -3,877,172 (Position Closed) | Filing History |
| 2024-11-14 4:28 pm Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 6,230,845 9.990% | 1,779,960 (+39.99%) | Filing History |
| 2024-11-12 4:26 pm Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,913,005 4.920% | 34,709 (+1.21%) | Filing History |
| 2024-11-12 2:22 pm Unchanged | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | The Vanguard Group | 3,071,580 5.190% | 0 (Unchanged) | Filing History |
| 2024-11-08 11:54 am Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | Farallon Capital Partners, L.P. | 3,527,482 6.000% | 427,482 (+13.79%) | Filing History |
| 2024-11-06 2:40 pm Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | GOLDMAN SACHS GROUP INC GS | 4,516,577 7.600% | 4,516,577 (New Position) | Filing History |
| 2024-11-04 11:49 am Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | The Vanguard Group | 3,071,580 5.190% | 3,071,580 (New Position) | Filing History |
| 2024-10-09 09:01 am Unchanged | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | EMPERY ASSET MANAGEMENT, LP | 4,000,000 4.990% | 0 (Unchanged) | Filing History |
| 2024-08-15 4:03 pm Purchase | 2024-08-06 | 13G | Elevation Oncology, Inc. ELEV | Great Point Partners, LLC | 3,877,172 6.560% | 3,877,172 (New Position) | Filing History |
| 2024-08-08 9:05 pm Sale | 2024-08-08 | 13D | Elevation Oncology, Inc. ELEV | venBio Global Strategic Fund III L.P. | 2,031,920 3.400% | -505,851 (-19.93%) | Filing History |